Plasma cell leukaemia | Zendy

Carlos Galvão Braga | Zendy; Ana Raquel Rodrigues | Zendy; Marina Alves | Zendy; Catarina Portela | Zendy; Luísa Pinto | Zendy; Herlander Marques | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Plasma cell leukaemia

Author(s) -

Carlos Galvão Braga,

Ana Raquel Rodrigues,

Marina Alves,

Catarina Portela,

Luísa Pinto,

Herlander Marques

Publication year - 2016

Publication title -

porto biomedical journal

Language(s) - English

Resource type - Journals

eISSN - 2444-8672

pISSN - 2444-8664

DOI - 10.1016/j.pbj.2016.04.001

Subject(s) - leukocytosis , medicine , plasmacytosis , bone marrow , vincristine , chemotherapy , plasma cell , dexamethasone , plasma cell leukemia , complication , bone pain , disease , pathology , gastroenterology , cyclophosphamide

Plasma cell leukaemia (PCL) is a rare and aggressive disease. Diagnosis is made when there are >2000/#mL circulating plasma cells in peripheral blood or plasmacytosis >20% of total leukocyte count. We report a case of a 51-year old man with generalized bone pain and constitutional symptoms. Blood peripheral smear revealed leukocytosis with 39% plasma cells. Bone marrow biopsy showed plasma cell invasion, which confirmed the diagnosis of PCL. Additionally, the patient had markers of advanced disease. Chemotherapy with vincristine, adriamycin and dexamethasone was started. Despite an initial favourable response, the patient died 2 months later due to an infectious complication. PCL has no established treatment and has a dismal prognosis, requiring the achievement of better data to improve the disease course

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research